BiotechTube

PRAM9 + Regular Insulin + Pramlintide + Regular Insulin

Phase 2Completed
0 watching 0 views this week⚡ Active
47
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Diabetes Mellitus, Type 1

Conditions

Diabetes Mellitus, Type 1, Insulin-dependent Diabetes Mellitus

Trial Timeline

Aug 22, 2019 → Apr 2, 2020

NCT ID
NCT04074317

About PRAM9 + Regular Insulin + Pramlintide + Regular Insulin

PRAM9 + Regular Insulin + Pramlintide + Regular Insulin is a phase 2 stage product being developed by Xeris Pharmaceuticals for Diabetes Mellitus, Type 1. The current trial status is completed. This product is registered under clinical trial identifier NCT04074317. Target conditions include Diabetes Mellitus, Type 1, Insulin-dependent Diabetes Mellitus.

Hype Score Breakdown

Clinical
17
Activity
12
Company
5
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT04074317Phase 2Completed

Competing Products

20 competing products in Diabetes Mellitus, Type 1

See all competitors
ProductCompanyStageHype Score
add-on pioglitazone + add-on sulphonylureaAMD BiotechApproved
77
MKP10241 + PlaceboMankind PharmaPhase 2
52
Daily injection of KBP/placebo for up to 28 daysEli LillyPhase 1
33
LY3209590 + Insulin DegludecEli LillyPhase 1
33
AC2993Eli LillyPhase 3
77
LY3209590 + PlaceboEli LillyPhase 1
33
Insulin Lispro Protamine Suspension + Insulin GlargineEli LillyPhase 3
77
LY2963016 + LantusEli LillyPhase 1
33
Empagliflozin + Other SGLT2 inhibitors + Other non-insulin GLDsEli LillyPre-clinical
23
Insulin Lispro Mix25 + Insulin Lispro Mix50Eli LillyApproved
85
Nasal Glucagon + Intramuscular GlucagonEli LillyPhase 3
77
Retatrutide + PlaceboEli LillyPhase 1
33
AG019 - Low Dose + Teplizumab + Placebo-AG019 + Placebo-Teplizumab + AG019 - High Dose + AG019 - High DosePrecigenPhase 1/2
36
LY4057996 SC + LY4057996 IV + Placebo SC + Placebo IV + Degludec SC + Lispro SC + Degludec IV + Pre-study basal insulin SCEli LillyPhase 1
33
Placebo + LinagliptinEli LillyPhase 3
77
Insulin Glargine + Insulin Lispro Premix (mid-mixture and low-mixture)Eli LillyApproved
85
teplizumab or placeboEli LillyPhase 1
33
LY2428757 + PlaceboEli LillyPhase 2
52
Insulin Efsitora Alfa + Insulin DegludecEli LillyPhase 3
77
LY900014 (SC) + LY900014 (IV)Eli LillyPhase 1
33

Other Products from Xeris Pharmaceuticals

G-Pen (glucagon injection) + Lilly Glucagon (glucagon injection [rDNA origin])Phase 3
72
G-Pen + Novo GlucagonPhase 3
72
G-Pen + Lilly GlucagonPhase 3
72
GlucagonPhase 3
72
Glucagon RTUPhase 2
47